Eczema tracks with low vitamin D, and topping it up eased severity

Atopic dermatitis is one of the most common inflammatory skin conditions, and managing flare-ups is a long grind for the people who live with it. Recent literature had highlighted a possible role for vitamin D in the condition, raising two linked questions: do people with atopic dermatitis actually carry lower vitamin D levels than healthy people, and if so, does supplementing with vitamin D measurably improve the severity of their skin? This review set out to answer both questions by pooling the available evidence rather than relying on any single small study.

The authors searched the MEDLINE, EMBASE and Cochrane databases up to May 2015. They included studies that followed people as well as randomised controlled trials, provided each reported serum 25-hydroxyvitamin D levels, the standard blood marker of vitamin D status, and quantified eczema severity using either the SCORAD index or the EASI score. They then compared vitamin D levels between patients and healthy controls, and pooled the change in severity scores after vitamin D supplementation.

Compared with healthy controls, serum vitamin D was lower in atopic dermatitis patients of all ages, with a standardised mean difference of -2.03 ng/mL. The gap was predominantly driven by paediatric patients, where the difference reached -3.03 ng/mL. On the treatment side, SCORAD and EASI severity scores decreased after vitamin D supplementation, with a standardised mean difference of -5.85 and a range from -7.66 to -4.05. The authors concluded that vitamin D supplementation could be a new therapeutic option for the condition.

This pooling strengthens the case that vitamin D status and eczema are connected, extending vitamin D's story well beyond bone health. The association alone cannot establish direction: low vitamin D could contribute to eczema, or living with eczema could lower vitamin D. The supplementation trials make the causal case more persuasive, but the abstract does not address what dose, what duration or which patients benefit most, and the search ended in 2015, so later trials sit outside this synthesis. Those remain the open questions.

For anyone managing eczema, this is a reason to regard vitamin D as genuinely relevant to the condition rather than fringe speculation: sufferers ran measurably lower levels, and severity improved in trials of supplementation. It is not a promise that a supplement will clear anyone's skin, and it is not a substitute for whatever treatment is already working. It is, at minimum, a conversation worth having and a blood marker worth understanding.